16227315

Source:http://linkedlifedata.com/resource/pubmed/id/16227315

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0023487, umls-concept:C0040845, umls-concept:C0052416, umls-concept:C0087111
pubmed:issue	1
pubmed:dateCreated	2005-12-19
pubmed:abstractText	Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Arsenicals, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion, http://linkedlifedata.com/resource/pubmed/chemical/Oxides, http://linkedlifedata.com/resource/pubmed/chemical/arsenic trioxide, http://linkedlifedata.com/resource/pubmed/chemical/promyelocytic leukemia-retinoic...
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	0923-7534
pubmed:author	pubmed-author:AghdamiNN, pubmed-author:AlimoghaddamKK, pubmed-author:BaharBB, pubmed-author:BaybordiEE, pubmed-author:GhaffariS HSH, pubmed-author:GhavamzadehAA, pubmed-author:HosseiniRR, pubmed-author:IravaniMM, pubmed-author:JahaniMM, pubmed-author:KhodabadehAA, pubmed-author:MortazaviYY, pubmed-author:MossaviAA, pubmed-author:RostamiSS, pubmed-author:TotonchiMM
pubmed:issnType	Print
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	131-4
pubmed:dateRevised	2006-9-29
pubmed:meshHeading	pubmed-meshheading:16227315-Adolescent, pubmed-meshheading:16227315-Adult, pubmed-meshheading:16227315-Aged, pubmed-meshheading:16227315-Antineoplastic Agents, pubmed-meshheading:16227315-Arsenicals, pubmed-meshheading:16227315-Child, pubmed-meshheading:16227315-Disease-Free Survival, pubmed-meshheading:16227315-Female, pubmed-meshheading:16227315-Humans, pubmed-meshheading:16227315-Leukemia, Promyelocytic, Acute, pubmed-meshheading:16227315-Leukocytosis, pubmed-meshheading:16227315-Male, pubmed-meshheading:16227315-Middle Aged, pubmed-meshheading:16227315-Neoplasm, Residual, pubmed-meshheading:16227315-Neoplasm Proteins, pubmed-meshheading:16227315-Neoplasm Recurrence, Local, pubmed-meshheading:16227315-Oncogene Proteins, Fusion, pubmed-meshheading:16227315-Oxides, pubmed-meshheading:16227315-Prognosis, pubmed-meshheading:16227315-Remission Induction, pubmed-meshheading:16227315-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:16227315-Survival Rate, pubmed-meshheading:16227315-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
pubmed:affiliation	Haematology, Oncology and BMT Research Centre, Tehran University of Medical Sciences, Tehran, Iran.
pubmed:publicationType	Journal Article